Avinash Gupta
Overview
Explore the profile of Avinash Gupta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
945
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nisar H, Rau N, Gohman T, Javed M, Gupta A
J Perinatol
. 2025 Feb;
PMID: 40000717
No abstract available.
2.
Bai X, Shaheen A, Grieco C, dArienzo P, Mina F, Czapla J, et al.
EClinicalMedicine
. 2024 Apr;
71:102564.
PMID: 38572079
No abstract available.
3.
Gohman T, Nisar H, Gupta A, Javed M, Rau N
Int J Comput Assist Radiol Surg
. 2024 Feb;
19(5):881-889.
PMID: 38400949
Purpose: Exposure to procedures varies in the neonatal intensive care unit (NICU). A method to teach procedures should be available without patient availability, expert oversight, or simulation laboratories. To fill...
4.
Singh N, Gupta A, Kumar S, Mawalankar G, Gupta B, Dhole N, et al.
J Hematop
. 2024 Jan;
16(1):17-25.
PMID: 38175369
Presence of measurable residual disease (MRD) in acute myeloid leukemia (AML) is considered to be an independent predictor of relapse and poorer survival outcomes. MRD can be measured by flow...
5.
Dayimu A, Gupta A, Matin R, Nobes J, Board R, Payne M, et al.
Eur J Cancer
. 2023 Nov;
196:113455.
PMID: 38029480
Background: BRAF+MEK inhibitors extend life expectancy of patients with BRAF mutant advanced melanoma. Acquired resistance limits duration of benefit, but preclinical and case studies suggest intermittent dosing could overcome this...
6.
Bai X, Shaheen A, Grieco C, dArienzo P, Mina F, Czapla J, et al.
EClinicalMedicine
. 2023 Nov;
65:102290.
PMID: 37965433
Background: Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant therapies for patients with stage III V600-mutant melanoma. However, there is still a lack of head-to-head comparative data. We...
7.
Cooksley T, Knight T, Lindsay D, Gupta A, Ho J, Higham C, et al.
Clin Med (Lond)
. 2023 Jan;
23(1):81-84.
PMID: 36697002
Ambulatory emergency care forms a fundamental part of the strategy of trying to ensure safe and sustainable acute care services. Immune checkpoint inhibitor(ICI)-mediated hypophysitis is an important life-threatening complication of...
8.
Valpione S, Campana L, Weightman J, Salih Z, Galvani E, Mundra P, et al.
Eur J Cancer
. 2022 Nov;
177:164-174.
PMID: 36347135
Background: Immune cell-driven anti-cancer activity is paramount for effective responses to checkpoint inhibitors (ICB). However, the contribution of the different immune cell subsets in the circulation and within the tumour...
9.
Frazer R, Gupta A, Herbert C, Payne M, Diaz-Mendoza S, Vincent S, et al.
Ther Adv Med Oncol
. 2022 Nov;
14:17588359221127681.
PMID: 36339928
Purpose: Dabrafenib and trametinib combination therapy (dab + tram) is indicated to treat BRAF V600 mutation-positive unresectable/metastatic melanoma and as adjuvant treatment for resected stage III disease. Dab + tram-related...
10.
Srivastava A, Gupta A, Chauhan D, Meena R, Sugadev R, Rao Eslavath M, et al.
Appl Microbiol Biotechnol
. 2022 Aug;
106(18):6225-6238.
PMID: 35976427
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has adversely affected humankind and caused millions of deaths globally since January 2020. Robust and quick serological tests such as antibody detection...